Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic
Under clinical development since the early 90's and with two successfully approved drugs (Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a clinical drug to the market in the cancer field. Whilst many pre-clinical data has been generated, a lack of understan...
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | article |
| Idioma: | eng |
| Publicado em: |
2014
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/120730 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/120730 |